Sleep Apnea - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Sleep Apnea - Pipeline Review, H2 2016', provides an overview of the Sleep Apnea pipeline landscape. The report provides comprehensive information on the therapeutics under development for Sleep Apnea, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Sleep Apnea and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Sleep Apnea - The report reviews pipeline therapeutics for Sleep Apnea by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Sleep Apnea therapeutics and enlists all their major and minor projects - The report assesses Sleep Apnea therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Sleep Apnea Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Sleep Apnea - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Sleep Apnea pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Sleep Apnea Overview 6 Therapeutics Development 7 Pipeline Products for Sleep Apnea - Overview 7 Pipeline Products for Sleep Apnea - Comparative Analysis 8 Sleep Apnea - Therapeutics under Development by Companies 9 Sleep Apnea - Therapeutics under Investigation by Universities/Institutes 10 Sleep Apnea - Pipeline Products Glance 11 Late Stage Products 11 Clinical Stage Products 12 Early Stage Products 13 Sleep Apnea - Products under Development by Companies 14 Sleep Apnea - Products under Investigation by Universities/Institutes 15 Sleep Apnea - Companies Involved in Therapeutics Development 16 Galleon Pharmaceuticals 16 RespireRx Pharmaceuticals Inc. 17 SK Biopharmaceuticals Co., Ltd. 18 Vivus, Inc. 19 Sleep Apnea - Therapeutics Assessment 20 Assessment by Monotherapy Products 20 Assessment by Combination Products 21 Assessment by Target 22 Assessment by Mechanism of Action 24 Assessment by Route of Administration 26 Assessment by Molecule Type 27 Drug Profiles 28 (phentermine + topiramate) ER - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 CX-1739 - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 dronabinol - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 GAL-475 - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 GAL-475 Backups - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 SKL-N05 - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 Small Molecule for Sleep Apnea - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 Sleep Apnea - Dormant Projects 46 Sleep Apnea - Discontinued Products 47 Sleep Apnea - Product Development Milestones 48 Featured News & Press Releases 48 Jun 14, 2016: Jazz Pharmaceuticals Presents New Data from a Human Abuse Liability Study for JZP-110, an Investigational Treatment for Excessive Sleepiness in Patients with Narcolepsy or with Obstructive Sleep Apnea, at 30th Annual SLEEP Meeting 48 Feb 29, 2016: RespireRx Pharmaceuticals Announces Removal of FDA Clinical Hold on CX1739 and Initiation of Phase IIA Clinical Trial by March 31, 2016 49 Jun 08, 2015: Jazz Pharmaceuticals Announces First Patients Enrolled in Phase 3 Clinical Development Program Evaluating JZP-110 as a Potential Treatment of EDS Associated with Narcolepsy or with OSA 49 May 14, 2015: VIVUS Announces Scientific Presentations 50 May 04, 2015: Cortex Pharmaceuticals Announces Publication of Research Results on the Use of Ampakines CX1739 in the Treatment of Respiratory Disorders 51 May 04, 2015: Cortex Pharmaceuticals Announces Publication of Research Results on the Use of Ampakines CX1739 in the Treatment of Respiratory Disorders 52 May 15, 2014: VIVUS Announces Qsymia Presentation at the American Association of Clinical Endocrinologists 52 Jul 01, 2013: VIVUS Announces Initial Availability of Qsymia Through Certified Retail Pharmacies 53 Nov 12, 2012: Study Finds Significant Improvements In Patients With Obstructive Sleep Apnea Treated With Phentermine And Topiramate Extended-Release Capsules 54 Jan 09, 2012: VIVUS Provides Update On Regulatory Status Of Qnexa 55 Nov 03, 2011: FDA Accepts New Drug Application Filing For Qnexa 55 Apr 26, 2011: Cortex Receives US Patent For Lead AMPAKINE Molecule CX1739 56 Feb 02, 2011: Cortex's Ampakine CX1739 Improves Respiratory Parameters In Obstructive Sleep Apnea Patients 56 Jan 07, 2010: VIVUS Announces Positive Results From Phase II Study Of Qnexa In Obstructive Sleep Apnea 57 Appendix 59 Methodology 59 Coverage 59 Secondary Research 59 Primary Research 59 Expert Panel Validation 59 Contact Us 59 Disclaimer 60
List of Tables
Number of Products under Development for Sleep Apnea, H2 2016 7 Number of Products under Development for Sleep Apnea - Comparative Analysis, H2 2016 8 Number of Products under Development by Companies, H2 2016 9 Number of Products under Investigation by Universities/Institutes, H2 2016 10 Comparative Analysis by Late Stage Development, H2 2016 11 Comparative Analysis by Clinical Stage Development, H2 2016 12 Comparative Analysis by Early Stage Development, H2 2016 13 Products under Development by Companies, H2 2016 14 Products under Investigation by Universities/Institutes, H2 2016 15 Sleep Apnea - Pipeline by Galleon Pharmaceuticals, H2 2016 16 Sleep Apnea - Pipeline by RespireRx Pharmaceuticals Inc., H2 2016 17 Sleep Apnea - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2016 18 Sleep Apnea - Pipeline by Vivus, Inc., H2 2016 19 Assessment by Monotherapy Products, H2 2016 20 Assessment by Combination Products, H2 2016 21 Number of Products by Stage and Target, H2 2016 23 Number of Products by Stage and Mechanism of Action, H2 2016 25 Number of Products by Stage and Route of Administration, H2 2016 26 Number of Products by Stage and Molecule Type, H2 2016 27 Sleep Apnea - Dormant Projects, H2 2016 46 Sleep Apnea - Discontinued Products, H2 2016 47
Our library has over 100000 reports on 1000s of topics
Over 100+ Fortune 500 companies rely on us
90,000+ people come to us for insights every month
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.